Table 3.
Univariate and multivariable logistic regression assessing associations with the composite outcome
| Characteristics | Univariate | Multivariable | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| Clinical characteristics | ||||
| Age | 0.99 (0.96–1.02) | 0.53 | ||
| Gender | ||||
| Female | Reference | |||
| Male | 1.40 (0.63–3.13) | 0.41 | ||
| Weight | 1.00 (0.98–1.01) | 0.83 | ||
| Baseline SCr | 0.73 (0.48–1.11) | 0.14 | ||
| Charlson Comorbidity Index | 0.97 (0.88–1.07) | 0.60 | ||
| Daptomycin dosing | ||||
| Average dose | 1.13 (0.89–1.43) | 0.31 | ||
| Standard vs. high dose | ||||
| Standard dose | Reference | Reference | ||
| High dose | 1.02 (0.45–2.32) | 0.96 | 1.11 (0.46–2.69) | 0.81 |
| Frequency | ||||
| Q24h | Reference | |||
| Q48h | 0.45 (0.14–1.45) | 0.18 | ||
| With hemodialysis | 0.95 (0.08–10.91) | 0.97 | ||
| Other | 1.90 (0.26–14.17) | 0.53 | ||
| Concomitant medications during infectious course | ||||
| Statin | 0.70 (0.27–1.78) | 0.45 | ||
| Antihistamine | 2.88 (1.09–7.57) | 0.033 | 3.24 (1.16–9.02) | 0.025 |
| Antibiotics | ||||
| Ampicillin | 4.40 (0.39–50.15) | 0.23 | ||
| Piperacillin–tazobactam | 2.48 (1.11–5.52) | 0.026 | 2.37 (1.02–5.53) | 0.045 |
| Cefazolin | 1.06 (0.09–12.03) | 0.96 | ||
| Ceftriaxone | 0.66 (0.22–1.97) | 0.45 | ||
| Cefepime | 0.96 (0.42–2.21) | 0.92 | ||
| Ceftazidime–avibactam | 4.40 (0.39–50.15) | 0.23 | ||
| Ceftolozane–tazobactam | 11.05 (0.26–464.89) | 0.21 | ||
| Ertapenem | 1.15 (0.48–2.73) | 0.75 | ||
| Meropenem | 1.25 (0.49–3.16) | 0.64 | ||
| Ciprofloxacin | 3.91 (0.88–17.33) | 0.073 | ||
| Levofloxacin | 3.35 (0.54–20.99) | 0.20 | ||
| Vancomycin | 1.15 (0.51–2.61) | 0.73 | ||
| Linezolid | 0.35 (0.07–1.66) | 0.19 | ||
| Gentamicin | 11.05 (0.26–464.89) | 0.21 | ||
| Metronidazole | 0.90 (0.38–2.10) | 0.80 | ||
| Other antibiotic | 4.32 (1.18–15.83) | 0.027 | 4.04 (1.04–15.62) | 0.043 |